Navigation Links
DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Date:1/29/2009

will expand its scope to all indications currently treated by radiotherapy and chemotherapy. The ability of siDNA to improve therapeutic efficacy without additional cytotoxicity has potential to extend the market for radiotherapy and chemotherapy. It is anticipated that DNA Therapeutics will have a pipeline with products at different stages of development within the next 5 years, throughout balanced proprietary and partnered programs, thus achieving rapidly significant value creation and providing the exit opportunity for its initial investors.

About SGAM SEFTI

SGAM SEFTI (Specialized European fund for Therapeutic Innovation) is a venture fund dedicated to investments in unlisted French and European companies operating principally in the pharmaceutical field and in medico-surgical applications. The fund acquires interests in the firms which it accompanied through the set-up stage in order to develop and increase the value of innovative therapeutic projects coming mainly from academic research in France, Switzerland and Italy. SGAM SEFTI investment is focused in target companies at an initial stage of development and which have further development opportunities with the potential to provide a capital gain in the medium term through licensing and sale.

    Contacts:

    DNA Therapeutics
    Prof. Jian-Sheng Sun, Ph.D.
    Chairman and CEO
    Phone: +33-624-753-239
    Email: sun@dna-therapeutics.com

    SGAM SEFTI
    Dr. Beatrice Denys, M.D., MBA
    Manager of the fund
    Phone: +33-156-378-712
    Email: Beatrice.denys@sgam.com


'/>"/>
SOURCE DNA Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Baptist Health Lexington is the first facility in ... with Electrophysiology Services (EPS) Accreditation status from the Society of ... most common cardiac arrhythmia and has become recognized as a ... and possible death. More than 5 million patients in ... the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... CITY, Kan. , Dec. 18, 2014 /PRNewswire/ ... PETX ), a biopharmaceutical company focused on the ... companion animals, today announced positive results from its ... innovative drug for treating pain in dogs with ... improvements in pain assessment scores that were statistically ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
Breaking Medicine Technology:Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... 30 Sirion Therapeutics, Inc. announced today ... products, pipeline and research will be presented ... Association for Research in Vision and Ophthalmology ... http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )These presentations include ...
... Two Phase 3 studies to start in the second ... Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: ... are extending their global development program for VEGF Trap-Eye, ... diseases, to include Central Retinal Vein Occlusion (CRVO). The ...
Cached Medicine Technology:Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 2Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 4Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 5
(Date:12/22/2014)... 2014 Coral Gables is preparing to welcome ... Troopers, with its new clinic location set to open in ... hassle out of dealing with this common childhood parasite by ... two salon clinic locations in South Florida, or in the ... decision to expand developed naturally out of the demand for ...
(Date:12/22/2014)... New York (PRWEB) December 22, 2014 The ... a staple of the season. Many may be thinking about ... a span of a few weeks. Health Republic Insurance of ... of Registered Dietitian, Andrea Chernus, to provide some smart ideas ... and stay healthy. , 1)    Avoid arriving at a holiday gathering ...
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Only weeks ... southern and mid-western cities to have a battery manufacturer ... TalkLocal ( http://www.talklocal.com ) is launching in Henderson ... economy. , “A strong manufacturing sector is going ... founder Gurpreet Singh explained, “and TalkLocal works with small ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... latest issue of Deutsches rzteblatt International ( ... research group presents epidemiological data. The authors surveyed ... specializing in the treatment of HIV patients in the ... to analyze the largest collection of data on the ...
... care information systems is a multibillion dollar industry. The ... to talk to each other regularly attract media comment. However ... Open Source, that could address many of these problems, because ... systems. Now new research by the University of Warwick,s ...
... Metabolomics is a post-genomic research field for analysis of ... approaches offer an analysis of metabolite level changes in ... in identifying the new diagnostic markers and therapeutic targets ... scarce. A research article to be published on ...
... an inflammatory obliterative cholangiopathy with unknown etiology, leading ... as an indispensable research tool for gene expression ... underlying BA, and allows the simultaneous analysis of ... studies have been performed to investigate the gene ...
... The best prescription for patients with venous leg ulcers is ... A five-year study led from the University of Leeds ... the healing process of leg ulceration contrary to what ... cheaper and easier to deliver, work just as well, the ...
... Reporter , MONDAY, March 7 (HealthDay News) -- Interactive ... kids, metabolisms to levels typically seen with moderate or ... the effect of six forms of so-called "exergaming" on ... (BMIs) at a youth fitness research and training center ...
Cached Medicine News:Health News:Resaerch finds open-source software is actually more secure for health care IT 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Video Games That Make Kids Move Burn Calories 2
Inquire...
Inquire...
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
Medicine Products: